*A HealthTech Reporter & IPHA Feature -in Collaboration with the AngioInstitute Research Group*
With a PhD in neuroscience, a
decorated background in inflammation research, and five years serving as
Director and Vice President of Research & Education for NeuFit, Ramona
embodies a new model of scientific leadership—merging academic rigor with
disruptive clinical innovation. Her role at WINBACK marks a critical milestone
for a company poised to redefine radiofrequency therapy in the United States.
A Scientist at the Helm
WINBACK, originally founded in
France in 2012, has long been regarded in Europe as an innovator in TECAR/RF
therapy—a modality built on radiofrequency energy designed to accelerate
tissue healing, reduce inflammation, and support cellular function. Yet the
United States remains largely underdeveloped in its adoption of these tools.
Ramona understands this gap well: “All of our research has been in Europe…
but clinical validation in the U.S. is essential for the next phase of growth.”
Her scientific philosophy is
refreshingly clear-cut: technology must match the body’s natural intelligence.
“The body can heal itself, but sometimes it just needs the right support,”
she explained, reflecting on her transition away from pharmaceutical-based
inflammation studies and into regenerative medicine.
WINBACK’s Signature Breakthrough: Radiofrequency
as a Recovery Enhancer
When Ramona describes WINBACK technology, it becomes immediately evident that this is not simply another device entering the U.S. therapy market. WINBACK’s system is built on dual-frequency radiofrequency energy and EMS (electrical muscle stimulation), capable of working at multiple depths—from superficial dermal layers to deep musculotendinous tissues.
“We work with different
frequencies depending on the depth you want to reach… every tissue has
resonance,” she explained. “We are helping to support the cell
permeability, vascularization, nutrient flow… it’s energy interacting with the
body’s own current.”
Her enthusiasm is grounded in both
science and long-term observation: RF therapy in Europe is decades ahead of
U.S. adoption, showcasing strong clinical results across:
- Sports medicine & athletic recovery
- Women’s pelvic health and postpartum care
- Aesthetic and wellness applications
- Pain modulation & inflammation reduction
The practical advantage? WINBACK
uses programmable frequencies that precisely target tissue layers,
enabling practitioners to choose frequencies that target different depths and
tissue types—an innovation Ramona believes is unmatched in the market.
Why
Women’s Health Is WINBACK’s Fastest-Growing Vertical
“When we host an event for
women’s health, the response is through the roof,” she shared. “There is
a level of interest, engagement, and need that surpasses every other vertical.”
This includes pelvic floor therapy,
incontinence, postpartum recovery, endometriosis, and sexual health—areas long
underserved by traditional medicine. As she emphasized, “Pelvic health isn’t
just a women’s issue… it’s a preventative and functional issue for everyone.”
WINBACK
Meets the AngioInstitute:
A Shared Vision for Scientific
Validation**
The meeting with the AngioInstitute, led by world-renowned cancer imaging specialist Dr. Robert L. Bard, introduced Ramona to a group deeply committed to objective, image-guided validation of emerging medical technologies.
Dr. Bard, known as the “cancer
detective,” operates one of the nation’s most advanced ultrasound-based
diagnostic labs. His philosophy is simple: If a technology claims
therapeutic impact, imaging should prove it.
The AngioInstitute Research Group
presented WINBACK with a collaborative pathway:
- Before/after ultrasound imaging
- Elastography for tissue quality changes
- Doppler vascular studies
- Thermology for inflammatory shifts
Their offer was not just
scientific—it was invitational. “Visual documentation is essential. If
findings show improvement clinically and scientifically, the world will believe
it,” the team expressed during the meeting.
This aligns perfectly with WINBACK’s 2025 mandate: expand
U.S. clinical evidence through strategic research partnerships. Ramona
acknowledged it directly: “The studies from France are great, but they’re
not enough for the U.S. market. Clinical validation here is absolutely
essential.”
Toward
a New Era of Regenerative Medicine
“Everyone responds to different
forms of energy,” she emphasized. “RF works with the body’s current…
it’s a universal medium for tissue healing.”
Her approach mirrors a shift
unfolding across integrative medicine:
- From reaction → to prevention
- From pharmaceutical management → to cellular
optimization
- From isolated treatments → to multimodal
regenerative strategies
WINBACK does not replace other
modalities—it enhances them.
A
Promising Partnership Ahead
WINBACK
is an ideal fit. As one participant put it, “When somebody else writes about
you, it becomes journalism. When we validate your outcomes, it becomes science.”
Conclusion:
The Ramona Effect
Ramona von Leden’s leadership
represents more than a corporate appointment; it signals WINBACK’s commitment
to scientific credibility, practitioner empowerment, and patient-centered
healing.
She brings clarity to a field often
clouded by hype, offering a grounded understanding of what radiofrequency
therapy can truly achieve—when guided by the right science, the right partners,
and the right mission.
These initial conversations between
WINBACK, HealthTech Reporter, IPHA, and the AngioInstitute signal the beginning
of a new collaborative chapter—one where radiofrequency innovation meets
uncompromising clinical validation. If the future of non-invasive medicine
has a name, Ramona von Leden is helping write it.
